Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14112075 | 0.91 | OXTR (0.48) | OXTRCYP2D6HSD11B1 | |
| SCHEMBL4408255 | 0.84 | OXTR (0.48) | OXTRHSD11B1 | |
| SCHEMBL8472020 | 0.81 | OXTR (0.57) | OXTRHSD11B1 | |
| Hydrochloric Acid SCHEMBL7383656 | 0.80 | OXTR (0.55) | OXTRHSD11B1 | |
| SCHEMBL4233731 | 0.79 | OXTR (0.46) | OXTRHSD11B1 | |
| SCHEMBL15717910 | 0.78 | OXTR (0.51) | OXTRHSD11B1 | |
| SCHEMBL12183908 | 0.78 | OXTR (0.54) | OXTRHSD11B1 | |
| SCHEMBL14671958 | 0.78 | OXTR (0.54) | OXTRHSD11B1 | |
| SCHEMBL1671212 | 0.78 | OXTR (0.54) | OXTRHSD11B1 | |
| SCHEMBL8012161 | 0.77 | MCHR2 (0.58) | OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138834-B1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-20180134707-A1 | AZASPIRO[4.5]DECANE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2018-05-17 | — | — | US | disclosed |
| US-9884865-B2 | Azaspiro[4.5] decane derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9868763-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-01-16 | — | — | US | disclosed |
| US-9868763-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-01-16 | — | — | US | disclosed |
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| EP-2864331-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | BRISTOL MYERS SQUIBB CO (US) | 2017-08-09 | — | — | EP | disclosed |
| US-9701711-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-11 | — | — | US | disclosed |
| US-9682980-B2 | Positive allosteric modulators of mGluR2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150152113-A1 | Positive Allosteric Modulators of MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-04 | — | — | US | disclosed |
| US-20150038402-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | UNIV QUEENSLAND (AU) | 2015-02-05 | — | — | US | disclosed |
| US-8927503-B2 | Modulations of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-01-06 | — | — | US | disclosed |
| US-8901085-B2 | — | — | 2014-12-02 | — | — | US | disclosed |
| US-20140315796-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-10-23 | — | — | US | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130184226-A1 | MODULATIONS OF PROTEASE ACTIVATED RECEPTORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-07-18 | — | — | US | disclosed |
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | OXTR 796/4885CYP2D6 519/4885HSD11B1 251/4885 |
| US-20180134707-A1 | AZASPIRO[4.5]DECANE DERIVATIVES AND USE THEREOF | TRPV1, SCN5A, TRPA1 | OXTR 239/4885CYP2D6 266/4885HSD11B1 830/4885 |
| US-20150152113-A1 | Positive Allosteric Modulators of MGLUR2 | GRM2, GRM1, GRIN2A | OXTR 220/4885CYP2D6 3912/4885HSD11B1 3396/4885 |
| US-20130184226-A1 | MODULATIONS OF PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | OXTR 1985/4885CYP2D6 1831/4885HSD11B1 1135/4885 |
| US-20140315796-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | OXTR 2027/4885CYP2D6 2733/4885HSD11B1 742/4885 |
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | OXTR 923/4885CYP2D6 317/4885HSD11B1 38/4885 |
| US-20150038402-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | OXTR 2067/4885CYP2D6 1719/4885HSD11B1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.